Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd has been selected to present its late-breaking abstract at the ESMO Congress 2024, detailing promising Phase IIb trial results for its novel immunotherapy eftilagimod alpha in combination with pembrolizumab for treating head and neck cancer. This significant milestone underscores the potential of eftilagimod alpha to improve outcomes for patients with PD-L1 positive head and neck squamous cell carcinoma. The company is at the forefront of LAG-3 immunotherapy development, aiming to offer new treatment options for cancer and autoimmune diseases.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
